New York, NY – According to filings with the U.S. Securities and Exchange Commission, Dracen Pharmaceuticals is raising $17,046,698.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Tom Estok played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Dracen Pharmaceuticals
Dracen is a private pharmaceutical company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types. Our goal in treating cancers is to directly shrink tumors and remodel the tumor microenvironment to make it more conducive to immuno-oncology approaches, to gain greater disease control, increase anti-tumor responses and extend patient survival in areas of unmet need. This includes cancers that possess genetic mutations which may make them highly susceptible to our therapies and those able to evade available immuno-oncology and other standard-of-care approaches.

To learn more about Dracen Pharmaceuticals, visit http://www.dracenpharma.com/

Contact:
Tom Estok, Chief Executive Officer
917-398-3710
testok@tragarapharma.com
https://www.linkedin.com/in/tom-estok-4b81471/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved